MJA
MJA

Human papillomavirus vaccine coverage among female Australian adolescents: success of the school-based approach

Med J Aust 2013; 199 (9): 614-617. || doi: 10.5694/mja13.10272

Summary

Objective: To describe quadrivalent human papillomavirus (HPV) vaccination coverage achieved in the HPV vaccination catch-up program for girls aged 12–17 years.

Design: Analysis of data from the Australian National HPV Vaccination Program Register.

Participants: Girls aged 12–17 years as at 30 June 2007.

Main outcome measures: HPV vaccine coverage by dose (1, 2 and 3), age and state of residence, using Australian Bureau of Statistics estimates of resident populations as the denominator.

Results: Notified vaccination coverage for girls aged 12–17 years nationally was 83% for dose 1, 78% for dose 2 and 70% for dose 3. The Australian Capital Territory and Victoria recorded the highest three-dose coverage for the 12–17-year-old cohort overall at 75%. The highest national three-dose coverage rate by age was achieved in 12-year-olds (74%). In Queensland, coverage among Indigenous girls compared with non-Indigenous girls was lower with each dose (lower by 4% for dose 1, 10% for dose 2 and 15% for dose 3). This pattern was not seen in the NT, where initial coverage was 17% lower among Indigenous girls, but the course completion rate among those who started vaccination was identical (84%).

Conclusions: The catch-up HPV vaccination program delivered over 1.9 million doses of HPV vaccine to girls aged 12–17 years, resulting in 70% of girls in this age group being fully vaccinated. The range in coverage achieved and the lower uptake documented among Indigenous girls suggest that HPV vaccination programs can be further improved.

  • Julia M L Brotherton1,2
  • Sharron L Murray3
  • Madeline A Hall4
  • Lynne K Andrewartha5
  • Carolyn A Banks6
  • Dennis Meijer7
  • Helen C Pitcher8
  • Megan M Scully9
  • Luda Molchanoff10

  • 1 National HPV Vaccination Program Register, Victorian Cytology Service, Melbourne, VIC.
  • 2 Discipline of Paediatrics and Child Health, University of Sydney, Sydney, NSW.
  • 3 Centre for Disease Control, Darwin, NT.
  • 4 Queensland Health, Brisbane, QLD.
  • 5 Communicable Diseases Control Unit, Department of Health and Human Services, Hobart, TAS.
  • 6 Communicable Diseases Control, ACT Health, Canberra, ACT.
  • 7 Communicable Diseases Branch, Health Protection NSW, NSW Health, Sydney, NSW.
  • 8 Department of Health, Melbourne, VIC.
  • 9 Communicable Disease Control Directorate, WA Health, Perth, WA.
  • 10 Department of Health and Ageing, Adelaide, SA.

Correspondence: jbrother@vcs.org.au

Acknowledgements: 

The NHVPR is owned by the Department of Health and Ageing and managed by the Victorian Cytology Service. We wish to thank all the immunisation program managers and the immunisation teams who delivered the program across Australia, and to specifically acknowledge Vicki Bryant, Kerry Nettle, Genevieve Chappell, Lesley Rowlands, Karen Winch, Christine Selvey and Karen Peterson for assistance with the preparation of this paper.

Competing interests:

Julia Brotherton was a partner investigator on an Australian Research Council linkage grant on which bioCSL was a partner investigator.

  • 1. Brotherton JM. How much cervical cancer in Australia is vaccine preventable? A meta-analysis. Vaccine 2008; 26: 250-256.
  • 2. Ball SL, Winder DM, Vaughan K, et al. Analyses of human papillomavirus genotypes and viral loads in anogenital warts. J Med Virol 2011; 83: 1345-1350.
  • 3. Australian Bureau of Statistics. Schools, Australia, 2010. Canberra: ABS. (ABS Cat. No. 4221.0.) http://www.abs.gov.au/AUSSTATS/abs@.nsf/Lookup/4221.0Main+Features12010? OpenDocument (accessed Jan 2013).
  • 4. Gertig DM, Brotherton JML, Saville M. Measuring human papillomavirus (HPV) vaccination coverage and the role of the National HPV Vaccination Program Register, Australia. Sex Health 2011; 8: 171-178.
  • 5. Chief Medical Officer. Guidance on revaccination where HPV vaccine doses have been given at less than recommended minimum intervals: January 2009. Canberra: Department of Health and Ageing, 2009. http://www.health.gov.au/internet/immunise/publishing.nsf/Content/cmo-full-advice-hpv-cnt/$File/CMO-full-advice-hpv.pdf (accessed Oct 2013).
  • 6. Leask J, Jackson C, Trevena L, et al. Implementation of the Australian HPV vaccination program for adult women: qualitative key informant interviews. Vaccine 2009; 27: 5505-5512.
  • 7. Brotherton J, Gertig D, Chappell G, et al. Catching up with the catch-up: HPV vaccination coverage data for Australian women aged 18-26 years from the National HPV Vaccination Program Register. Commun Dis Intell Q Rep 2011; 35: 197-201.
  • 8. Ali H, Donovan B, Wand H, et al. Genital warts in young Australians five years into national human papillomavirus vaccination programme: national surveillance data. BMJ 2013; 346: f2032.
  • 9. Tabrizi SN, Brotherton JM, Kaldor JM, et al. Fall in human papillomavirus prevalence following a national vaccination program. J Infect Dis 2012; 206: 1645-1651.
  • 10. Brotherton JM, Fridman M, May CL, et al. Early effect of the HPV vaccination programme on cervical abnormalities in Victoria, Australia: an ecological study. Lancet 2011; 377: 2085-2092.
  • 11. Queensland Department of Education and Training. Closing the Gap: education strategy. Brisbane: Queensland Government. http://deta.qld.gov.au/indigenous/pdfs/closing-gap-13072011.pdf (accessed Jan 2013).
  • 12. Northern Territory Department of Health. NT HPV Vaccination Program Remote Project Report June 2009. Dr Rosalind Webby, Head of Immunisation, NT Department of Health.
  • 13. Kulasingam S, Connelly L, Conway E, et al. A cost-effectiveness analysis of adding a human papillomavirus vaccine to the Australian National Cervical Cancer Screening Program. Sex Health 2007; 4: 165-175.
  • 14. Centers for Disease Control and Prevention. National and state vaccination coverage among adolescents aged 13-17 years – United States, 2011. MMWR Morb Mortal Wkly Rep 2012; 61: 671-677.
  • 15. Fagot JP, Boutrelle A, Ricordeau P, et al. HPV vaccination in France: uptake, costs and issues for the National Health Insurance. Vaccine 2011; 29: 3610-3616.
  • 16. Information Services Division Scotland. HPV immunisation uptake statistics. HPV Immunisation Programme – School Year 2011/12. Publication date – 25 September 2012. http://www.isdscotland.org/Health-Topics/Child-Health/Publications/2012-09-25/2012-09-25-HPV-Uptake-Report.pdf?49483889342 (accessed Jan 2013).
  • 17. Potts A, Sinka K, Love J, et al. High uptake of HPV immunisation in Scotland — perspectives on maximising uptake. Euro Surveill 2013; 18: pii=20593.
  • 18. O’Donnell H, Broun K, Mullins R. A new partnership approach to school-based HPV immunisation in Victoria. Presented at the 13th National Immunisation Conference; 2012 Jun 19-21; Darwin, NT, Australia.
  • 19. Ogilvie G, Anderson M, Marra F, et al. A population-based evaluation of a publicly funded, school-based HPV vaccine program in British Columbia, Canada: parental factors associated with HPV vaccine receipt. PLOS Med 2010; 7: e1000270.
  • 20. Cooper Robbins SC, Bernard D, McCaffery K, et al. “Is cancer contagious?”: Australian adolescent girls and their parents: making the most of limited information about HPV and HPV vaccination. Vaccine 2010; 28: 3398-3408.
  • 21. Mak DB, Bulsara M, Goggin LS, Effler PV. Resending a consent form and information package to non-responders increases school-based consent return rate. Aust N Z J Public Health 2011; 35: 89-90.
  • 22. Watson M, D’Onise K, Lynch J, Brotherton JML. What are the barriers to better three-dose coverage with HPV vaccination in school based programs? Aust N Z J Public Health 2013. In press.
  • 23. Brotherton JML, Mullins RM. Will vaccinated women attend cervical screening? A population based survey of human papillomavirus vaccination and cervical screening among young women in Victoria, Australia. Cancer Epidemiol 2012; 36: 298-302.
  • 24. Kouyoumdjian FG, Bailowitz A. Completion of the human papillomavirus vaccine series in females attending an urban immunization clinic. Pediatr Infect Dis J 2011; 30: 718-719.
  • 25. Watson M, Shaw D, Molchanoff L, McInnes C. Challenges, lessons learned and results following the implementation of a human papilloma virus school vaccination program in South Australia. Aust N Z J Public Health 2009; 33: 365-370.
  • 26. Queensland Health Immunisation Program. Evaluation of the School Based Vaccination Program (2007-2009) Stakeholders’ report. Brisbane: Queensland Government. http://www.health.qld.gov.au/immunisation/documents/sbvpevaluation.pdf (accessed Jan 2013).
  • 27. Australian Institute of Health and Welfare. National best practice guidelines for collecting Indigenous status in health data sets. Canberra: AIHW, 2010. (AIHW Cat. No. IHW 29.) http://www.aihw. gov.au/publication-detail/?id=6442468342& tab=2 (accessed Oct 2013).

Author

remove_circle_outline Delete Author
add_circle_outline Add Author

Comment
Do you have any competing interests to declare? *

I/we agree to assign copyright to the Medical Journal of Australia and agree to the Conditions of publication *
I/we agree to the Terms of use of the Medical Journal of Australia *
Email me when people comment on this article